Aug 22 (Reuters) - Regeneron Pharmaceuticals on Tuesday said it had entered into a contract worth $326 million with a U.S. government agency for the development of next-generation antibody therapy for COVID-19 prevention. (Reporting by Pratik Jain in Bengaluru; Editing by Maju Samuel)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,053 USD | +0.84% | +1.60% | +19.91% |
Jun. 20 | Declaration of Voting Results by Regeneron Pharmaceuticals, Inc | CI |
Jun. 18 | Alvotech Enters Commercialization Deal for Eylea Biosimilars with Advanz Pharma | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.91% | 114B | |
+15.19% | 121B | |
+8.24% | 23.61B | |
-19.80% | 20.43B | |
-16.19% | 16.55B | |
-13.45% | 16.45B | |
-44.35% | 15.59B | |
+66.67% | 15.19B | |
+2.13% | 13.54B | |
+119.39% | 10.96B |
- Stock Market
- Equities
- REGN Stock
- News Regeneron Pharmaceuticals, Inc.
- Regeneron enters $326 mln pact with US to develop new COVID therapy